Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

被引：1
|
作者：
Venditti, Adriano [1 ]
Hou, Jing-Zhou [2 ]
Fenaux, Pierre [3 ]
Jonas, Brian A. [4 ]
Vrhovac, Radovan [5 ,6 ]
Montesinos, Pau [7 ]
Garcia, Jacqueline S. [8 ]
Rizzieri, David [9 ]
Thirman, Michael J. [10 ]
Kotey, Stanley [11 ]
Potluri, Jalaja [11 ]
Dhalla, Mazaher [11 ]
Pullarkat, Vinod [12 ]
机构：
[1] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy
[2] UPMC Hillman Canc Ctr, Lemieux Ctr Blood Canc, Hematol & BMT, Pittsburgh, PA USA
[3] Univ Paris, St Louis Hosp, Dept Hematol, Paris, France
[4] Univ Calif Davis, Div Malignant Hematol Cellular Therapy & Transpla, Dept Internal Med, Sch Med, Sacramento, CA USA
[5] Univ Hosp Ctr Zagreb, Dept Haematol, Zagreb, Croatia
[6] Univ Zagreb, Sch Med, Zagreb, Croatia
[7] Hosp Univ & Politecn La Fe, Valencia, Spain
[8] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[9] Novant Hlth Canc Inst, Winston Salem, NC USA
[10] Univ Chicago, Sect Hematol Oncol, Dept Med, Chicago, IL USA
[11] AbbVie Inc, N Chicago, IL USA
[12] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182045
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Yamamoto, Kazuhito
    Shinagawa, Atsushi
    DiNardo, Courtney D.
    Pratz, Keith W.
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Komatsu, Norio
    Nakashima, Yasuhiro
    Yoshida, Chikashi
    Fukuhara, Noriko
    Usuki, Kensuke
    Yamauchi, Takahiro
    Asada, Noboru
    Asou, Norio
    Choi, Ilseung
    Miyazaki, Yasushi
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Zhou, Ying
    Zha, Jiuhong
    Potluri, Jalaja
    Matsumura, Itaru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 29 - 38
  • [2] Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Alary, Anne-Sophie
    Saillard, Colombe
    Hicheri, Yosr
    Mohty, Bilal
    Rey, Jerome
    D'Incan, Evelyne
    Charbonnier, Aude
    Villetard, Ferdinand
    Maisano, Valerio
    Lombardi, Laura
    Ittel, Antoine
    Mozziconacci, Marie-Joelle
    Gelsi-Boyer, Veronique
    Vey, Norbert
    CANCERS, 2022, 14 (08)
  • [3] Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
    Cherry, Evan M.
    Abbott, Diana
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Rosser, Julie
    Sato, Audrey
    Schowinsky, Jeffrey
    Inguva, Anagha
    Minhajuddin, Mohd
    Pei, Shanshan
    Stevens, Brett
    Winters, Amanda
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    BLOOD ADVANCES, 2021, 5 (24) : 5565 - 5573
  • [4] Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
    Richard-Carpentier, Guillaume
    DiNardo, Courtney D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [5] The propriety of upgrading responses to venetoclax plus azacitidine in newly diagnosed patients with acute myeloid leukemia
    Abbott, Diana
    Cherry, Evan
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Winters, Amanda
    Schowinsky, Jeffrey
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    LEUKEMIA & LYMPHOMA, 2021, 62 (06) : 1466 - 1473
  • [6] Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
    Agarwal, Sonal
    Kowalski, Andrew
    Schiffer, Molly
    Zhao, Jennifer
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (02) : 199 - 210
  • [7] Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective
    Pratz, Keith W.
    Chai, Xinglei
    Xie, Jipan
    Yin, Lei
    Nie, Xiaoyu
    Montez, Melissa
    Iantuono, Erica
    Downs, Lisa
    Ma, Esprit
    BLOOD, 2021, 138
  • [8] Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study
    Pratz, Keith W.
    DiNardo, Courtney D.
    Selleslag, Dominik
    Li, Junmin
    Yamamoto, Kazuhito
    Konopleva, Marina
    McDonald, Andrew
    Babu, Sunil
    Stevens, Don A.
    Kantarjian, Hagop M.
    Traina, Fabiola
    Venditti, Adriano
    Mayer, Jiri
    Montez, Melissa
    Ramsingh, Giridharan
    Jin, Huan
    Ainsworth, William
    Duan, Yinghui
    Svensson, Anders Erik
    Werner, Michael
    Potluri, Jalaja
    Jonas, Brian A.
    BLOOD, 2020, 136
  • [9] Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment
    Ikezoe, Takayuki
    Usuki, Kensuke
    Aida, Kensuke
    Hatayama, Tomoyoshi
    Shirahase, Toru
    Yamauchi, Takahiro
    CANCER SCIENCE, 2023, 114 (03) : 1037 - 1044
  • [10] Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Xia, Leiming
    Tian, Wanlu
    Zhao, Yiming
    Jiang, Lingling
    Qian, Wei
    Jiang, Lei
    Ge, Ling
    Li, Jianjun
    Jin, Fengbo
    Yang, Mingzhen
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
12345